Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;25(1):3-6.
doi: 10.1038/cdd.2017.188.

Bcl-2 on the brink of breakthroughs in cancer treatment

John C Reed  1   2
Affiliations
Editorial

Bcl-2 on the brink of breakthroughs in cancer treatment

John C Reed. Cell Death Differ. 2018 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Molecules in clinical development that target Bcl-2 family proteins. Based on data available at www.clinictrials.gov, the figure indicates molecules targeting a Bcl-2 family protein that are currently in clinical development according to their phase of development. The sponsors of the molecules are indicated by color, as shown at the bottom
See this image and copyright information in PMC

References

    1. Ruefli-Brasse A, Reed JC. Therapeutics targeting Bcl-2 in haematological malignancies. Biochem J 2017474: 3643–3657. - PubMed
    1. Ashkenazi A et al. Nat Rev Drug Discov 2017; 16: 273–284. - PubMed
    1. Pekarsky Y, Balatti V, Croce CM. BCL2 and miR-15/16: from gene discovery to treatment. Cell Death Differ 2017. (in press). - PMC - PubMed
    1. Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ 2017. (in press). - PMC - PubMed
    1. Kale J, Osterlund EJ, Andrews DW. Bcl-2 family proteins: changing partners in the dance towards death.. Cell Death Differ 2017. (in press). - PMC - PubMed

Publication types

MeSH terms

Substances